Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study
Open Access
- 1 May 2023
- journal article
- research article
- Published by Elsevier BV in The Lancet Regional Health - Southeast Asia
- Vol. 12, 100141
- https://doi.org/10.1016/j.lansea.2023.100141
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsThe New England Journal of Medicine, 2021
- Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) studyVaccine, 2021
- SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionNature, 2021
- Covid-19: Protection from two doses of vaccine wanes within six months, data suggestPublished by BMJ ,2021
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialThe Lancet, 2021
- An acute-on-chronic health crisis in GazaThe Lancet, 2021
- Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic ReviewIndian Journal of Clinical Biochemistry, 2021
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008